Description

What Is ARA 290 Peptide?

ARA 290 peptide, also known by its international nonproprietary name Cibinetide, is a synthetic linear peptide of 11 amino acids modeled on the three-dimensional structure of helix B of erythropoietin. Unlike EPO, ARA-290 was designed so that it does not stimulate red blood cell production in research models. Instead, it was developed to selectively engage the innate repair receptor (IRR), a heteromeric complex of the EPO receptor and the β-common receptor (CD131).

Because of this selective receptor activity, the ARA 290 peptide has become a subject of interest in preclinical and clinical research on tissue protection, inflammation signaling, and peripheral nerve function.

ARA 290 Peptide Research Overview

ARA-290 has been studied in published scientific literature in the following areas:

Small fiber neuropathy research: Phase 2 clinical studies looked at cibinetide in subjects with sarcoidosis-associated small fiber neuropathy, measuring corneal nerve fiber density and neuropathic symptom scores.
Metabolic and diabetic neuropathy models: Research investigated ARA-290 in type 2 diabetes-associated neuropathy and metabolic markers.
Nerve regeneration and tissue repair: Preclinical studies explored the peptide’s role in IRR-mediated anti-inflammatory and tissue-protective signaling.

These summaries describe published research only. They are not claims of therapeutic benefit. This product is not intended to diagnose, treat, cure or prevent any disease.

Certificate of Analysis Document

Detailed purity verification and batch analysis results

PDF
Click to view PDF
oml-ara290-10mg__combo__20260803__oml-z-26210__2608030506.pdf

Research

Scientific research related to this compound

Innate Repair Receptor Signalling — Research describes ARA-290 activating an EPO receptor / CD131 heterodimer expressed on injured tissue, separating tissue-protective signalling from erythropoiesis. ( https://pubmed.ncbi.nlm.nih.gov/29392190/
Small-Fibre Neuropathy — Investigated in sarcoidosis-related small-fibre neuropathy models and early-phase clinical research. ( https://pubmed.ncbi.nlm.nih.gov/24555851/
Diabetic Macular Edema — Evaluated in a Phase 2 clinical trial. ( https://pubmed.ncbi.nlm.nih.gov/32674280/
Innate Immune Modulation — Shown to dampen innate immune cell function in an experimental colitis model. ( https://pubmed.ncbi.nlm.nih.gov/29026145/
Pancreatic Islet Protection — Studied for islet protection under stress and improved engraftment in transplantation models. ( https://pubmed.ncbi.nlm.nih.gov/34498509/

References

Citations and reference materials

Targeting the innate repair receptor to treat neuropathy (Pain Rep, 2016) https://pubmed.ncbi.nlm.nih.gov/29392190/
ARA 290 for treatment of small fiber neuropathy in sarcoidosis (Expert Opin Investig Drugs, 2014) https://pubmed.ncbi.nlm.nih.gov/24555851/
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (J Clin Med, 2020) https://pubmed.ncbi.nlm.nih.gov/32674280/
Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis (Sci Rep, 2017) https://pubmed.ncbi.nlm.nih.gov/29026145/
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment (Cell Transplant, 2021) https://pubmed.ncbi.nlm.nih.gov/34498509/
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand (Transplantation, 2020) https://pubmed.ncbi.nlm.nih.gov/32345869/

Mechanism of Action

How this compound works at a biological level

In published research, ARA-290 (Cibinetide) has been investigated for mechanisms including: ARA-290 is an 11-amino acid peptide derived from the helix-B surface domain of erythropoietin (EPO). It selectively binds the innate repair receptor, a heterodimer of the EPO receptor and the β-common receptor (CD131), which is expressed on injured and inflamed tissue rather than on erythroid progenitors. Because it does not engage the homodimeric EPO receptor, it has been studied for tissue-protective and anti-inflammatory signalling without the red-blood-cell-stimulating activity of EPO. Mechanistic descriptions reflect findings in laboratory and animal-model research only.

Technical Details

Specifications, properties, and technical data

Compound type: Single
CAS number: 1208243-50-8
PubChem CID: 91810664 (https://pubchem.ncbi.nlm.nih.gov/compound/91810664)
Physical form: Lyophilized powder
Purity: ≥ 99% (HPLC; see batch Certificate of Analysis)
Size: 10mg
Storage: -20°C (lyophilized), 4°C (reconstituted)
Handling notes: Lyophilized: Store at −20°C for long-term stability; keep dry and protected from light. Reconstituted: Refrigerate at 2–8°C; use within 3–4 weeks. Avoid repeated freeze–thaw cycles. Allow vials to reach room temperature before opening to reduce condensation uptake.

ARA 290 Peptide (Cibinetide) 10mg

Our Third-Party Testing Commitment

Description

Certificate of Analysis Document

Research

References

Mechanism of Action

Technical Details

Related Products

TB-500 10mg

COA

Pentadeca Arginate (LL37) 5mg

KPV 10mg

COA

GLOW Lite 55mg

ARA 290 Peptide (Cibinetide) 10mg

Our Third-Party Testing Commitment

Description

Certificate of Analysis Document

Research

References

Mechanism of Action

Technical Details

Related Products

TB-500 10mg

COA

Pentadeca Arginate (LL37) 5mg

KPV 10mg

COA

GLOW Lite 55mg

Age & Research Verification

Verification Required